Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AzentaAZTA -1.95%78 Days Payable is 37.25 as of Jun. 2026, which is 22% below its 10-year median of 47.66. GuruFocus rates AZTA with a GF Score™ of 78/100 and a GF Value™ of $52.25 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 794 Medical Devices & Instruments companies, Azenta ranks worse than 75.57% on this metric.
Azenta's average Accounts Payable for the
three
months ended in Jun. 2026 was $36.3 Mil. Azenta's Cost of Goods Sold for the
three
months ended in Jun. 2026 was $88.8 Mil.
Hence, Azenta's Days Payable for the
three
months ended in Jun. 2026 was 37.25.
The historical rank and industry rank for Azenta's Days Payable or its related term are showing as below:
AZTA'
s Days Payable Range Over the Past 10 Years
Min: 39.58 Med: 47.66 Max: 94.78
Current: 39.75
During the past 13 years, Azenta's highest Days Payable was 94.78. The lowest was 39.58. And the median was 47.66.
AZTA's Days Payable is ranked worse than 75.57% of 794
companies
in the Medical Devices & Instruments industry
Industry Median: 68.505
vs AZTA: 39.75
Azenta's Days Payable
declined
from Jun. 2025 (45.44) to Jun. 2026 (37.25).
It may suggest that Azentaaccelerated paying its suppliers.
The historical data trend for Azenta's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Azenta's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Azenta Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Azenta's Days Payable distribution charts can be found below:
* The bar in red indicates where Azenta's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Azenta's Days Payable for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Azenta (AZTA) has a Days Payable of 37.25 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Azenta and its competitors. This is 22% below median its historical median of 47.66. Over the past decade, Azenta's Days Payable has ranged from 39.58 to 94.78. According to the industry distribution chart, Azenta ranks #600 out of 794 companies in the Medical Devices & Instruments industry, placing it in the top 75.6%.
Is Azenta's Days Payable too high?
Azenta's current Days Payable of 37.25 is 22% below median its 10-year median of 47.66. Over the past 10 years, this metric has ranged from a low of 39.58 to a high of 94.78. The Medical Devices & Instruments industry median Days Payable is 68.51. Azenta's value of 37.25 is 45.6% below this industry median. Based on the distribution chart, Azenta ranks #600 out of 794 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Azenta has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Azenta's Days Payable compare to KMTS and STAA?
According to the Medical Devices & Instruments industry distribution chart, Azenta ranks #600 out of 794 companies for Days Payable. This places Azenta in the lower half of its industry. The industry median Days Payable is 68.51. Azenta's value of 37.25 is 45.6% below this benchmark. Historically, Azenta's own Days Payable has ranged from 39.58 to 94.78 over the past decade. While the company's 10-year median is 47.66 vs. the industry median of 68.51, Azenta has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.51, based on 794 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Azenta's current Days Payable of 37.25 is 45.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Azenta and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Azenta's current Days Payable is 37.25, which is 22% below median its own 10-year median of 47.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Azenta stock overvalued right now?
Based on GuruFocus' analysis, Azenta (AZTA) is currently considered Significantly Undervalued. The stock's GF Value™ is $52.25, compared to a current price of $32.96 — trading 36.9% below its estimated fair value. The current Days Payable is 37.25, which is 22% below median its 10-year median of 47.66 and 45.6% below the Medical Devices & Instruments industry median of 68.51. Azenta's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Azenta (AZTA), the current Days Payable is 37.25 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Azenta (AZTA) Overvalued in 2026?
Based on GuruFocus' analysis, Azenta stock appears to be undervalued.
The current stock price of $32.96 is trading 36.9% below its estimated GF Value™ of $52.25.
GuruFocus considers Azenta to be Significantly Undervalued.
Key valuation signals for AZTA:
Days Payable: 37.25 (22% below median its 10-year median of 47.66)
GF Value™: $52.25 vs. price of $32.96 (36.9% below fair value)
Industry Position: 45.6% below the Medical Devices & Instruments median (#600 of 794)
No single metric tells the full story. See the AZTA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.
78GF Score
Get the complete analysis for AZTA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AZTA has been successfully added to your 
